MONOPAR THERAPEUTICS INC

MNPR is the ticker symbol for Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company. MNPR stock represents equity ownership in the company and trades on the Nasdaq Capital Market. As a development-stage company, its value is closely tied to the progress of its drug candidates and clinical trial outcomes.

Recent performance for MNPR can vary significantly due to clinical trial news, financing activities, and broader biotech sector sentiment. To see the latest price changes, percentage moves, and volume, please check the current data displayed on this page, as these figures change throughout each trading session.

Assessing whether MNPR is overvalued or undervalued is challenging because the company is clinical-stage and may not have meaningful earnings or revenue. Traditional metrics like P/E ratios are often not applicable. Valuation is typically judged by comparing its market capitalization to the potential of its drug pipeline and cash position. Review the latest financial data on this page for context.

To buy MNPR stock, you need a brokerage account that offers access to Nasdaq-listed securities. Once your account is funded, you can place a market or limit order for MNPR during regular trading hours. Some brokers also allow extended-hours trading. The minimum investment depends on the share price and whether your broker supports fractional shares.

Monopar Therapeutics (MNPR) does not pay a regular dividend. As a clinical-stage biopharmaceutical company, it typically reinvests any available capital into research and development rather than returning cash to shareholders. Investors seeking income should look elsewhere. For any updates on a potential dividend policy, refer to official company announcements.

Key risks for MNPR include the high failure rate of clinical drug candidates, regulatory setbacks, and the need for additional capital, which can dilute existing shareholders. As a small-cap biotech, MNPR is also exposed to volatile trading, competition, and dependence on key partnerships. These factors can lead to significant price swings.